Cargando...
Profile of infliximab in the treatment of pediatric Crohn’s disease
In recent years, a novel biologic therapy with monoclonal antibodies against tumor necrosis factor-alpha has revolutionized the treatment of Crohn’s disease. Infliximab, the first biologic agent, has been demonstrated to considerably improve both clinical and endoscopic outcomes. In view of the grow...
Gardado en:
| Publicado en: | Pediatric Health Med Ther |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5683274/ https://ncbi.nlm.nih.gov/pubmed/29388577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PHMT.S64943 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|